Wellgistics Health Expands Distribution of GLP-1 Companion Muscle Loss Medical Food to Pharmacy Network

Reuters

Nov 14

Wellgistics Health Expands Distribution of GLP-1 Companion Muscle Loss Medical Food to Pharmacy Network

Wellgistics Health Inc. announced an expansion of its agreement with Tollo Health to distribute a GLP-1 companion muscle loss medical food to over 6,500 independent pharmacies and physicians. The product, a branded version of a proprietary formulation, is intended as an adjunct to GLP-1 therapies to help mitigate muscle loss during weight loss and after discontinuation of therapy. Additionally, Wellgistics Health expanded its antiviral offerings by adding the 3CL protease inhibitor supplement Tollovid® to its distribution agreement, alongside the galectin 1 & 3 inhibitor medical food Galectovid®, targeting patients with Long COVID.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102511) on November 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583012125"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583012125\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583012125?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583012125","market":"us","top_or_hot":-1,"title":"Wellgistics Health Expands Distribution of GLP-1 Companion Muscle Loss Medical Food to Pharmacy Network","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Wellgistics Health Expands Distribution of GLP-1 Companion Muscle Loss Medical Food to Pharmacy Network\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/WGRX\">Wellgistics Health Inc.</a> announced an expansion of its agreement with Tollo Health to distribute a GLP-1 companion muscle loss medical food to over 6,500 independent pharmacies and physicians. The product, a branded version of a proprietary formulation, is intended as an adjunct to GLP-1 therapies to help mitigate muscle loss during weight loss and after discontinuation of therapy. Additionally, Wellgistics Health expanded its antiviral offerings by adding the 3CL protease inhibitor supplement Tollovid® to its distribution agreement, alongside the galectin 1 &amp; 3 inhibitor medical food Galectovid®, targeting patients with Long COVID.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102511) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wellgistics Health Expands Distribution of GLP-1 Companion Muscle Loss Medical Food to Pharmacy Network</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWellgistics Health Expands Distribution of GLP-1 Companion Muscle Loss Medical Food to Pharmacy Network\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-14 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Wellgistics Health Expands Distribution of GLP-1 Companion Muscle Loss Medical Food to Pharmacy Network\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/WGRX\">Wellgistics Health Inc.</a> announced an expansion of its agreement with Tollo Health to distribute a GLP-1 companion muscle loss medical food to over 6,500 independent pharmacies and physicians. The product, a branded version of a proprietary formulation, is intended as an adjunct to GLP-1 therapies to help mitigate muscle loss during weight loss and after discontinuation of therapy. Additionally, Wellgistics Health expanded its antiviral offerings by adding the 3CL protease inhibitor supplement Tollovid® to its distribution agreement, alongside the galectin 1 &amp; 3 inhibitor medical food Galectovid®, targeting patients with Long COVID.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102511) on November 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WGRX","symbol_name":"Wellgistics Health Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL4JJ9qd:1","article_id":"2583012125","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583012125","pubTimestamp":1763128825,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Wellgistics Health Inc. announced an expansion of its agreement with Tollo Health to distribute a GLP-1 companion muscle loss medical food to over 6,500 independent pharmacies and physicians. The product, a branded version of a proprietary formulation, is intended as an adjunct to GLP-1 therapies to help mitigate muscle loss during weight loss and after discontinuation of therapy. Additionally, Wellgistics Health expanded its antiviral offerings by adding the 3CL protease inhibitor supplement Tollovid to its distribution agreement, alongside the galectin 1 & 3 inhibitor medical food Galectovid, targeting patients with Long COVID.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WGRX":"Wellgistics Health Inc.","BK4175":"保健护理产品经销商"},"translate_title":"Wellgistics Health扩大GLP-1伴随肌肉损失医疗食品在药房网络的分销","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WGRX":0.9},"content_text":"Wellgistics Health Expands Distribution of GLP-1 Companion Muscle Loss Medical Food to Pharmacy Network\n    \n\nWellgistics Health Inc. announced an expansion of its agreement with Tollo Health to distribute a GLP-1 companion muscle loss medical food to over 6,500 independent pharmacies and physicians. The product, a branded version of a proprietary formulation, is intended as an adjunct to GLP-1 therapies to help mitigate muscle loss during weight loss and after discontinuation of therapy. Additionally, Wellgistics Health expanded its antiviral offerings by adding the 3CL protease inhibitor supplement Tollovid® to its distribution agreement, alongside the galectin 1 & 3 inhibitor medical food Galectovid®, targeting patients with Long COVID.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1102511) on November 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}